drugset / Trial / NCT07365904

Investigating Ovulation Inhibition for Use as a Contraceptive

NCT07365904

Phase 2 Recruiting 60 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelTreatment

Summary

A single-centre, open-label, randomised, phase II study on the maintenance of ovulation inhibition after intentional application errors during 84 days of treatment with MR 130A 01 contraceptive transdermal patch

Timeline

Start
2025-12-22
Primary completion
2026-11-30
Completion
2026-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject norelgestromin Unknown Other

Indications

No indication recorded.